 Joel Marrs
Concepts (168)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antihypertensive Agents | 5 | 2021 | 442 | 1.870 |
Why?
| | Hypertension | 7 | 2021 | 1140 | 1.760 |
Why?
| | Aspirin | 3 | 2015 | 285 | 1.460 |
Why?
| | Platelet Aggregation Inhibitors | 3 | 2015 | 343 | 1.400 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 6 | 2020 | 394 | 1.170 |
Why?
| | Diabetes Mellitus, Type 2 | 7 | 2017 | 1866 | 1.160 |
Why?
| | Atrial Fibrillation | 2 | 2019 | 330 | 1.070 |
Why?
| | Anticoagulants | 2 | 2019 | 509 | 1.040 |
Why?
| | Stroke | 4 | 2019 | 873 | 0.980 |
Why?
| | Thiophenes | 2 | 2015 | 107 | 0.930 |
Why?
| | Allylamine | 2 | 2012 | 8 | 0.910 |
Why?
| | Hypolipidemic Agents | 3 | 2011 | 94 | 0.880 |
Why?
| | Internship, Nonmedical | 2 | 2010 | 18 | 0.770 |
Why?
| | Medication Reconciliation | 1 | 2018 | 27 | 0.740 |
Why?
| | Kidney Failure, Chronic | 2 | 2011 | 418 | 0.650 |
Why?
| | Dyslipidemias | 3 | 2019 | 161 | 0.650 |
Why?
| | Cardiovascular Diseases | 6 | 2019 | 1633 | 0.630 |
Why?
| | Cholesterol, LDL | 5 | 2019 | 317 | 0.610 |
Why?
| | Pharmaceutical Services | 2 | 2020 | 76 | 0.610 |
Why?
| | Heart Failure, Diastolic | 1 | 2015 | 25 | 0.600 |
Why?
| | Pharmacists | 5 | 2020 | 234 | 0.600 |
Why?
| | Drug-Eluting Stents | 1 | 2015 | 78 | 0.590 |
Why?
| | Thromboembolism | 1 | 2015 | 98 | 0.580 |
Why?
| | Ticlopidine | 1 | 2015 | 66 | 0.580 |
Why?
| | Medically Underserved Area | 1 | 2015 | 100 | 0.570 |
Why?
| | Hypoglycemic Agents | 2 | 2012 | 932 | 0.560 |
Why?
| | Practice Guidelines as Topic | 5 | 2019 | 1541 | 0.550 |
Why?
| | Education, Pharmacy | 3 | 2017 | 152 | 0.520 |
Why?
| | Patient Discharge | 2 | 2018 | 675 | 0.520 |
Why?
| | Venous Thromboembolism | 1 | 2015 | 177 | 0.510 |
Why?
| | Piperazines | 1 | 2015 | 308 | 0.500 |
Why?
| | Thrombosis | 1 | 2015 | 244 | 0.500 |
Why?
| | Urban Population | 1 | 2015 | 415 | 0.500 |
Why?
| | Blood Pressure | 3 | 2016 | 1703 | 0.490 |
Why?
| | Guideline Adherence | 1 | 2016 | 522 | 0.490 |
Why?
| | Glucosides | 1 | 2012 | 31 | 0.490 |
Why?
| | Anticholesteremic Agents | 2 | 2012 | 141 | 0.450 |
Why?
| | Spironolactone | 1 | 2010 | 38 | 0.440 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2010 | 57 | 0.430 |
Why?
| | Preceptorship | 1 | 2010 | 55 | 0.410 |
Why?
| | Administration, Oral | 3 | 2019 | 796 | 0.400 |
Why?
| | Humans | 37 | 2021 | 109171 | 0.400 |
Why?
| | Professional Role | 3 | 2020 | 156 | 0.380 |
Why?
| | Medication Therapy Management | 2 | 2020 | 67 | 0.380 |
Why?
| | Students, Pharmacy | 1 | 2010 | 115 | 0.380 |
Why?
| | Benzodiazepines | 1 | 2008 | 110 | 0.360 |
Why?
| | Drug Therapy, Combination | 4 | 2016 | 1021 | 0.350 |
Why?
| | Renal Dialysis | 1 | 2010 | 304 | 0.350 |
Why?
| | Angiotensin Receptor Antagonists | 2 | 2021 | 68 | 0.340 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 3 | 2021 | 221 | 0.340 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2007 | 41 | 0.340 |
Why?
| | Sleep Initiation and Maintenance Disorders | 1 | 2008 | 114 | 0.340 |
Why?
| | Hypnotics and Sedatives | 1 | 2008 | 159 | 0.340 |
Why?
| | Hospitalization | 2 | 2015 | 1580 | 0.330 |
Why?
| | Insurance Coverage | 1 | 2008 | 204 | 0.330 |
Why?
| | Certification | 3 | 2013 | 111 | 0.320 |
Why?
| | Family Practice | 2 | 2010 | 471 | 0.320 |
Why?
| | Heart Failure | 1 | 2018 | 1806 | 0.310 |
Why?
| | Schools, Pharmacy | 2 | 2017 | 58 | 0.300 |
Why?
| | Faculty | 2 | 2017 | 110 | 0.290 |
Why?
| | Poverty | 1 | 2008 | 436 | 0.280 |
Why?
| | Ambulatory Care | 1 | 2007 | 452 | 0.260 |
Why?
| | Specialization | 3 | 2013 | 120 | 0.260 |
Why?
| | Colesevelam Hydrochloride | 2 | 2012 | 8 | 0.230 |
Why?
| | Aged | 9 | 2020 | 19759 | 0.230 |
Why?
| | Pharmacy Service, Hospital | 2 | 2013 | 84 | 0.230 |
Why?
| | Cell Phone | 1 | 2021 | 66 | 0.220 |
Why?
| | Retrospective Studies | 6 | 2021 | 10640 | 0.220 |
Why?
| | Cardiovascular Agents | 1 | 2021 | 128 | 0.210 |
Why?
| | Diabetes Mellitus | 2 | 2020 | 879 | 0.210 |
Why?
| | Brain Ischemia | 2 | 2013 | 265 | 0.210 |
Why?
| | Secondary Prevention | 3 | 2016 | 243 | 0.210 |
Why?
| | Text Messaging | 1 | 2021 | 128 | 0.200 |
Why?
| | Female | 12 | 2021 | 61606 | 0.200 |
Why?
| | Blood Glucose | 3 | 2012 | 1779 | 0.180 |
Why?
| | Heart Valve Diseases | 1 | 2019 | 180 | 0.180 |
Why?
| | Age Factors | 2 | 2016 | 3307 | 0.180 |
Why?
| | Middle Aged | 9 | 2020 | 28539 | 0.170 |
Why?
| | 4-Hydroxycoumarins | 1 | 2016 | 7 | 0.170 |
Why?
| | Dissociative Disorders | 1 | 2016 | 23 | 0.170 |
Why?
| | Vitamin K | 1 | 2016 | 44 | 0.170 |
Why?
| | Cholesterol | 3 | 2019 | 382 | 0.160 |
Why?
| | Community Participation | 1 | 2017 | 129 | 0.160 |
Why?
| | Risk Factors | 5 | 2019 | 8786 | 0.160 |
Why?
| | Clinical Trials as Topic | 2 | 2012 | 992 | 0.160 |
Why?
| | Patient Transfer | 1 | 2018 | 150 | 0.160 |
Why?
| | Male | 10 | 2020 | 60174 | 0.160 |
Why?
| | Aged, 80 and over | 4 | 2015 | 6709 | 0.150 |
Why?
| | Primary Prevention | 2 | 2014 | 216 | 0.150 |
Why?
| | Suicide, Attempted | 1 | 2016 | 243 | 0.140 |
Why?
| | Guidelines as Topic | 1 | 2016 | 276 | 0.140 |
Why?
| | Blood Coagulation Disorders | 1 | 2016 | 212 | 0.140 |
Why?
| | Diuretics | 2 | 2011 | 82 | 0.140 |
Why?
| | Adult | 7 | 2021 | 31455 | 0.140 |
Why?
| | Treatment Outcome | 2 | 2019 | 8928 | 0.130 |
Why?
| | Societies, Pharmaceutical | 2 | 2017 | 26 | 0.130 |
Why?
| | Atherosclerosis | 1 | 2015 | 274 | 0.130 |
Why?
| | Medication Adherence | 2 | 2021 | 512 | 0.120 |
Why?
| | Follow-Up Studies | 3 | 2016 | 4830 | 0.120 |
Why?
| | Acute Disease | 1 | 2015 | 993 | 0.120 |
Why?
| | Benzhydryl Compounds | 1 | 2012 | 55 | 0.120 |
Why?
| | Cross-Sectional Studies | 1 | 2021 | 3985 | 0.120 |
Why?
| | Data Collection | 1 | 2014 | 658 | 0.120 |
Why?
| | Hyperlipidemias | 1 | 2012 | 145 | 0.120 |
Why?
| | Health Promotion | 1 | 2017 | 648 | 0.110 |
Why?
| | Universities | 1 | 2013 | 353 | 0.110 |
Why?
| | Continuity of Patient Care | 1 | 2013 | 273 | 0.110 |
Why?
| | Sex Factors | 1 | 2016 | 1949 | 0.110 |
Why?
| | Drug Resistance | 1 | 2010 | 187 | 0.100 |
Why?
| | Pregnancy | 1 | 2021 | 5006 | 0.100 |
Why?
| | Interinstitutional Relations | 1 | 2010 | 67 | 0.100 |
Why?
| | United States | 6 | 2019 | 11627 | 0.100 |
Why?
| | Drug Monitoring | 1 | 2010 | 217 | 0.100 |
Why?
| | Myocardial Infarction | 1 | 2016 | 1111 | 0.090 |
Why?
| | Coronary Artery Disease | 1 | 2015 | 674 | 0.090 |
Why?
| | Dipeptidyl Peptidase 4 | 1 | 2007 | 8 | 0.090 |
Why?
| | Receptors, GABA-A | 1 | 2008 | 133 | 0.090 |
Why?
| | Adamantane | 1 | 2007 | 19 | 0.090 |
Why?
| | Patient-Centered Care | 1 | 2013 | 451 | 0.090 |
Why?
| | Pyrrolidines | 1 | 2007 | 40 | 0.090 |
Why?
| | Eicosapentaenoic Acid | 1 | 2006 | 33 | 0.080 |
Why?
| | Hypertriglyceridemia | 1 | 2006 | 43 | 0.080 |
Why?
| | Exercise | 1 | 2017 | 1608 | 0.080 |
Why?
| | Nitriles | 1 | 2007 | 123 | 0.080 |
Why?
| | Practice Patterns, Physicians' | 1 | 2015 | 1182 | 0.080 |
Why?
| | Docosahexaenoic Acids | 1 | 2006 | 65 | 0.080 |
Why?
| | Young Adult | 4 | 2015 | 10686 | 0.080 |
Why?
| | Insurance, Health | 1 | 2008 | 256 | 0.080 |
Why?
| | Aging | 1 | 2016 | 1696 | 0.080 |
Why?
| | Fatty Acids, Omega-3 | 1 | 2006 | 123 | 0.080 |
Why?
| | Hyperglycemia | 1 | 2009 | 328 | 0.080 |
Why?
| | Risk Assessment | 2 | 2016 | 3086 | 0.070 |
Why?
| | Triglycerides | 1 | 2006 | 537 | 0.070 |
Why?
| | Animals | 3 | 2012 | 34608 | 0.070 |
Why?
| | Adolescent | 4 | 2015 | 18208 | 0.070 |
Why?
| | Patient Compliance | 1 | 2008 | 618 | 0.070 |
Why?
| | Enzyme Inhibitors | 1 | 2007 | 933 | 0.060 |
Why?
| | Sleep | 1 | 2008 | 669 | 0.060 |
Why?
| | Curriculum | 1 | 2006 | 753 | 0.050 |
Why?
| | Annual Reports as Topic | 1 | 2017 | 7 | 0.050 |
Why?
| | Pragmatic Clinical Trials as Topic | 1 | 2017 | 37 | 0.050 |
Why?
| | Colorado | 1 | 2008 | 4514 | 0.040 |
Why?
| | Organizational Policy | 1 | 2017 | 76 | 0.040 |
Why?
| | Advisory Committees | 1 | 2017 | 196 | 0.040 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2021 | 1114 | 0.040 |
Why?
| | Eating | 1 | 2016 | 330 | 0.030 |
Why?
| | Mechanical Thrombolysis | 1 | 2013 | 5 | 0.030 |
Why?
| | Clinical Competence | 2 | 2011 | 881 | 0.030 |
Why?
| | Adrenergic Antagonists | 1 | 2011 | 8 | 0.030 |
Why?
| | Telephone | 1 | 2013 | 158 | 0.030 |
Why?
| | Thrombolytic Therapy | 1 | 2013 | 113 | 0.030 |
Why?
| | Renin | 1 | 2011 | 37 | 0.030 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 1 | 2011 | 43 | 0.030 |
Why?
| | Phytotherapy | 1 | 2011 | 71 | 0.030 |
Why?
| | Calcium Channel Blockers | 1 | 2011 | 163 | 0.030 |
Why?
| | Drug Utilization | 1 | 2011 | 189 | 0.030 |
Why?
| | Cohort Studies | 1 | 2020 | 4804 | 0.030 |
Why?
| | Patient Care Management | 1 | 2010 | 61 | 0.030 |
Why?
| | Hospitals, University | 1 | 2010 | 193 | 0.030 |
Why?
| | Governing Board | 1 | 2009 | 6 | 0.030 |
Why?
| | Prospective Studies | 1 | 2020 | 5942 | 0.020 |
Why?
| | Length of Stay | 1 | 2013 | 1056 | 0.020 |
Why?
| | Databases, Factual | 1 | 2013 | 1172 | 0.020 |
Why?
| | Patient Readmission | 1 | 2013 | 597 | 0.020 |
Why?
| | Inpatients | 1 | 2010 | 310 | 0.020 |
Why?
| | Prevalence | 1 | 2013 | 2329 | 0.020 |
Why?
| | Drug Combinations | 1 | 2006 | 281 | 0.020 |
Why?
| | Primary Health Care | 1 | 2015 | 1452 | 0.020 |
Why?
|
|
Marrs's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|